ES3030540T3 - Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077 - Google Patents

Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077

Info

Publication number
ES3030540T3
ES3030540T3 ES22713478T ES22713478T ES3030540T3 ES 3030540 T3 ES3030540 T3 ES 3030540T3 ES 22713478 T ES22713478 T ES 22713478T ES 22713478 T ES22713478 T ES 22713478T ES 3030540 T3 ES3030540 T3 ES 3030540T3
Authority
ES
Spain
Prior art keywords
gdc
combination therapy
patient
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22713478T
Other languages
English (en)
Spanish (es)
Inventor
Ciara Metcalfe
Xiaojing Wang
Wei Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80953424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3030540(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES3030540T3 publication Critical patent/ES3030540T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
ES22713478T 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077 Active ES3030540T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163149944P 2021-02-16 2021-02-16
PCT/US2022/016270 WO2022177844A1 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077

Publications (1)

Publication Number Publication Date
ES3030540T3 true ES3030540T3 (en) 2025-06-30

Family

ID=80953424

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22713478T Active ES3030540T3 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077

Country Status (8)

Country Link
US (1) US20230381155A1 (https=)
EP (1) EP4294395B1 (https=)
JP (1) JP2024506385A (https=)
CN (1) CN117377472A (https=)
ES (1) ES3030540T3 (https=)
PL (1) PL4294395T3 (https=)
TW (1) TWI808648B (https=)
WO (1) WO2022177844A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025163068A (ja) * 2022-11-02 2025-10-28 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化
KR20250107982A (ko) * 2022-11-02 2025-07-14 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 및 오르토스테릭 포켓 표적화

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102785474B1 (ko) 2014-12-18 2025-03-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
EP4212536B1 (en) 2015-07-02 2025-02-19 F. Hoffmann-La Roche AG Benzoxazepin oxazolidinone compounds and methods of use
US20170362228A1 (en) * 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
LT3810283T (lt) * 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
KR20210035211A (ko) * 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
CN115175679A (zh) * 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法

Also Published As

Publication number Publication date
TWI808648B (zh) 2023-07-11
EP4294395B1 (en) 2025-03-26
TW202237100A (zh) 2022-10-01
WO2022177844A1 (en) 2022-08-25
JP2024506385A (ja) 2024-02-13
CN117377472A (zh) 2024-01-09
US20230381155A1 (en) 2023-11-30
EP4294395A1 (en) 2023-12-27
EP4294395C0 (en) 2025-03-26
PL4294395T3 (pl) 2025-06-23

Similar Documents

Publication Publication Date Title
RU2737496C2 (ru) Способы лечения рака
Gul et al. A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach
JP2020158507A6 (ja) 放射線、酸化セリウムナノ粒子、及び化学療法剤の併用によるがんの治療
CN109310684B (zh) 用于治疗癌症的notch和cdk4/6抑制剂的组合疗法
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
US11576919B2 (en) Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant
JP2025038167A (ja) キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
ES3030540T3 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
US20240173306A1 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
JP2016520662A (ja) Ｐｉ３ｋ阻害剤および微小管不安定化剤の医薬組み合わせ
TWI881203B (zh) 使用包含gdc-9545及帕他色替之組合療法治療乳癌
HK40101173A (zh) 使用包括gdc-9545和gdc-0077的组合疗法治疗乳腺癌
JP7846700B2 (ja) Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
ES2670596T3 (es) Terapia de combinación para prevenir la formación del DCIS y la progresión hasta cáncer de mama
HK40129153A (zh) 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
HK40084792B (zh) 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
CN118829432A (zh) 用于治疗癌症的ras抑制剂和法尼基转移酶抑制剂的组合
HK40101825A (zh) 使用包括gdc-9545和依帕他赛的组合疗法治疗乳腺癌
HK40066922A (zh) 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌
Zeng Sequencing of type I insulin-like growth factor receptor inhibition with chemotherapy in breast cancer cells
NZ786604A (en) Combination therapy with notch and cdk4/6 inhibitors for the treatment of